Why Choose China for CAR-T?
World-class innovation, unmatched speed, and accessible pricing.
Unmatched Speed
Vein-to-vein time as fast as 14 days.
(vs 4-8 weeks in the US)
Accessible Cost
Total package from $60k - $120k.
(vs $450k+ in the US)
Cutting-Edge Innovation
Access to dual-target CAR-T (CD19/CD22) for relapsed patients who failed other treatments.
World-Class Clinical Partners
We provide direct access to the pioneers of CAR-T therapy in China. Partnering with Leading Hematology & Oncology Center & National Top-Ranked General Hospital (Beijing) to ensure the highest standard of care and safety.
JCI Accredited Facilities
Over 10,000+ Successful Cases
English-Speaking Medical Teams
Full Logistic Support